Industry Briefs: November 19, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.
Company News
Allergan has agreed to acquire SkinMedica’s topical aesthetics skin-care business. Read More
bioMérieux and Quanterix have entered into an agreement that gives bioMérieux worldwide exclusive rights to Quanterix’s Simoa technology in clinical laboratories and for industrial applications. Read More
GVK Biosciences has received approvals from the Atomic Energy Regulatory Board and the Indian government, to carry out 3H and 14C synthesis activities. Read More
Jubilant HollisterStier has announced that its contract manufacturing and services division has secured more than $100 million in contracts with leading pharmaceutical companies for the commercial manufacturing of multiple sterile parenteral products. Read More
Pacific BioLabs has acquired Bay Bioanalytical Laboratory, thus adding analytical and bioanalytical chemistry to Pacific BioLabs’ existing in vivo preclinical and microbiological testing services. Read More
Recipharm and Vetcare have entered into an agreement for the development and manufacture of a parenteral veterinary product. Read More
Sensient Pharmaceutical has extended its proprietary line of Microfine natural colors to provide a complete natural color coating system ideal for the nutraceutical market. Read More
Synerlab and AXA Private Equity have announced the acquisitions of Lyofal and IDD-TECH Orleans. Read More
People News
Onyx Scientific has appointed Dan Brisard business development director. Read More
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
